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Dr Frank A. Pigula (Boston, Mass). Dr Boni, thank you for
a good presentation and a good manuscript, and congratulations
to your team with this model. These are all difficult models to
perform.
I would note that this material, this SIS, has been used for vas-
cular reconstructions previously. And in fact, this particular prep-
aration has been approved by the Food and Drug Administration
for 3 applications: for pericardial replacement, for intracardiac
patching, and, more recently, in fact late last year, for carotid artery
patching as well.
With that being said, this is among the more careful studies that
I have come across in the literature. You have shown to my satis-
faction that there is a process of change in this SIS graft after im-
plantation and that it appears to transform into PA-like tissue with
time. I do, however, have a couple questions.
One is that you suggested that there was growth potential in the
tissue. Now, did you measure the patch that you put in or measure
the patch that you took out? And how can you be sure that it was
not compensatory growth from the surrounding PA?
Dr Boni. Thank you for the question, Dr Pigula.
We did measure the patch. We found that the patch, in the first
moment, was increasing its thickness, and probably this was due to
the activation of the inflammatory process, which we could seeThe Journal of Thoracic and Camainly in the adventitial layer, where we saw a lot of inflammatory
cells that populated the patch. The reason that we suggest the
growing idea is that when we later assessed the thickness of the
patch, we saw that the medial layer was increasing or growing,
but the full thickness of the patch was decreasing. So the inflam-
mation started to regress after 3 months, and the medial layer
started increasing in size. And apart from this, we could see the ap-
pearance of elastin fibers, which is a marker of an arterial wall.
We cannot say for sure that the patch was growing. We do know
that it was getting repopulated by cells, and we do not know ex-
actly from where they came. We saw CD117+ cells, but we do
not know how it was going, the processing.
Dr Pigula. I guess when I was referring to growth, I was refer-
ring to the surface area growth, rather than the thickness.
Dr Boni.Yes, that’s why I think we probably need longer exper-
iments, because I think the PAwall is an elastic tissue, and we may
need to place bigger patches and follow up for much longer to see
that it is growing in this area.
Dr Pigula.Well, that brings me to my other question regarding
the thickness of the patch and the composition of the patch with
time. You have shown that there was elastin in the tissue at the
end of the 6 months, but it was a fraction of what there is in the
normal PA. So one of the questions for people who may be im-
planting this is what is the mechanical strength of this tissue?
And if there is a transformative process, it is a balance between
degradation of one and regeneration of another and having a me-
chanically safe tissue.
Dr Boni. Yes, of course, this is a very good point. We did not
measure the mechanical force. Other studies did it before and dem-
onstrated a good mechanical force.
And also, measuring the patch, we saw that, for example, rela-
tive to the native PA, the medial layer was more or less a fifth the
full thickness in the patch, whereas in the arterial wall it was half,
with elastin fibers, a few fibers, at 6 months. So that is why I say
that we started to see that the patch was mimicking the arterial
wall, because probably this process was still ongoing. And we
should follow up such animals and do other studies for a longer pe-
riod to assess the complete remodeling, and probably to assess the
mechanical force.
We did not see any aneurysm formation, so in this study we
could not see any problem with the weakness of the patch.
Dr Pigula. Is it being used clinically in your institution?
Dr Boni. Yes, we have been using it clinically. In tiny PAs,
when they are very small, smaller than 3 mm, we have had some
problem, probably because of the initial phase of remodeling,
when the inflammatory process is higher, and we have had some
stenosis of these small structures. So we use it in bigger structures,
and also in PAs but not the tiny ones.rdiovascular Surgery c Volume 144, Number 4 969
